Oral antiviral treatments for COVID-19 during severe connective tissue disease flares: report of two cases.
ARP Rheumatol
; 1(4): 332-333, 2022.
Article
in English
| MEDLINE | ID: covidwho-2168247
ABSTRACT
Antiviral therapies targeting SARS-CoV-2 replication change the course of COVID-19. The European Medicines Agency (EMA) has approved a nirmatrelvir/ritonavir combination that inhibits the main protease of the virus. Molnupiravir, an RNA polymerase misdirector, is proposed by EMA in selected cases, despite still without marketing authorisation. Both are for use in mild disease with a high risk of progression to severe COVID. Patients with inflammatory rheumatic diseases under immunosuppression, mainly high-dose glucocorticoids, are at higher risk of developing severe COVID. We report two clinical cases in which nirmatrelvir/ritonavir and molnupiravir were successfully used to treat COVID-19 in immunosuppressed patients during severe flares of connective tissue diseases, namely systemic lupus erythematosus and dermatomyositis. No significant adverse events attributable to these drugs were noted.
Search on Google
Collection:
International databases
Database:
MEDLINE
Main subject:
Connective Tissue Diseases
/
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
ARP Rheumatol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS